JW (CAYMAN) THERAPEUTICS CO. LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.75 HKD | +1.74% |
|
+2.34% | -22.57% |
| Mar. 20 | JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023 | MT |
| Mar. 20 | JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2023 | 174M 24.02M 188M | Sales 2024 * | 268M 37.04M 290M | Capitalization | 654M 90.28M 707M |
|---|---|---|---|---|---|
| Net income 2023 | -768M -106M -830M | Net income 2024 * | -597M -82.47M -646M | EV / Sales 2023 | 0.79 x |
| Net cash position 2023 | 687M 94.92M 743M | Net cash position 2024 * | 313M 43.29M 339M | EV / Sales 2024 * | 1.27 x |
| P/E ratio 2023 |
-1.1
x | P/E ratio 2024 * |
-1.11
x | Employees | 398 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 76.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.74% | ||
| 1 week | +2.34% | ||
| Current month | -4.37% | ||
| 1 month | -6.42% | ||
| 3 months | -15.05% | ||
| 6 months | -5.91% | ||
| Current year | -22.57% |
1 week
1.65
1.85
1 month
1.611.96
Current year
1.582.42
1 year
1.583.52
3 years
1.5836.50
5 years
1.5852.80
10 years
1.5852.80
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Ping Li
CEO | Chief Executive Officer | 59 | 17-09-05 |
| Chief Tech/Sci/R&D Officer | 43 | 22-01-09 | |
Mark Gilbert
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Debra Yu
BRD | Director/Board Member | 59 | 23-02-28 |
Cheng Liu
BRD | Director/Board Member | 57 | 20-06-29 |
Yi Ping Li
CEO | Chief Executive Officer | 59 | 17-09-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.70% | 4 M€ | -27.92% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1.75 | +1.74% | 67,500 |
| 24-04-24 | 1.72 | -1.71% | 764,500 |
| 24-04-23 | 1.75 | +1.74% | 65,000 |
| 24-04-22 | 1.72 | 0.00% | 97,500 |
| 24-04-19 | 1.72 | +0.58% | 274,500 |
Delayed Quote Hong Kong S.E., April 25, 2024 at 04:09 am EDT
More quotes
JW Cayman Therapeutics Co Ltd is a China-based company mainly engaged in the clinical and pre-clinical stage cell therapy. The Company is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The Company mainly conducts its businesses in the China market.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.62
CNY
Average target price
2.508
CNY
Spread / Average Target
+54.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.57% | 88.61M | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- 2126 Stock
